Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 3,501–3,600 of 4,108
Who should be screened for osteoporosis?
Crandall, C. J., & Ensrud, K. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00062-9
Human immunodeficiency virus and osteoporosis
Brown, T. T., & Yin, M. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00049-6
Agnollitto, P. M. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-07092020-095401
Exercise and other physical therapy interventions in the management of osteoporosis
Giangregorio, L., & Katzman, W. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00069-1 · Cited by 1
Zahid, R., Zahid, S., Sajjad, R., Naseer, U., Qayyum, M., Ullah, I., Rafique, E., & Zahid, A. (2020) · Authorea · doi:10.22541/au.160315211.15850622/v1
Vertebral fracture identification
Griffith, J. F., & Genant, H. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00063-0
The skeletal actions of parathyroid hormone in primary hyperparathyroidism
Cusano, N. E., Bilezikian, J. P., & Silverberg, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00047-2
Braz, G. D. A. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.59.2020.tde-31072020-162346 · Cited by 1
Çiçek, E. D., Öztürk, G., & Aktaş, İ. (2020) · Journal of Surgery and Medicine · doi:10.28982/josam.790513
“vertebral fracture in patients older than 65 years increases the risk of a new vertebral fracture by 7 to 10-fold within 5 years [9,10].”
BackgroundFalls and Fall-Risk-Increasing Drugs (FRIDs)
Springer, S. P., & Carr, M. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.frids_overview
Bucuku, M. (2020) · Journal of Research and Practice on the Musculoskeletal System · doi:10.22540/jrpms-04-096
Park, E., Tran, B., Best, B. M., et al. (2017) · Journal of Contemporary Pharmacy Practice · doi:10.37901/jcphp16-00008
Uso de bifosfonatos en pacientes con osteopenia
Sguiglia, S. (2019) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v22i2.4239
Horta‐Baas, G. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001587
Tiwari, S., & Patel, R. (2020) · Journal of Clinical Research in HIV AIDS and Prevention · doi:10.14302/issn.2324-7339.jcrhap-20-3003
Alekseeva, Y. V., Semiglazova, Т. Y., Каспаров, Б., Ткаченко, Е. В., Proshchayeu, K. I., Бриш, Н. А., Филатова, Л. В., Семиглазов, В. В., Voronina, E. A., Касымов, Р. Х., et al. (2020) · Advances in Gerontology · doi:10.1134/s2079057020040025
Nurshanty, A., Wardhani, S. O., & Suryana, B. P. P. (2020) · Clinical and Research Journal in Internal Medicine · doi:10.21776/ub.crjim.2020.001.01.4
“75%It shows that 2 out of 5 Indonesians are at risk for osteoporosis, and this figure is higher than the global prevalence of which only 1 in 3 is at risk of osteoporosis.([5,6,7]) WHO defines osteoporosis based on bone mineral density (BMD).”
BackgroundBone mineral density and nourishment
Ćatović, A., Ersan, B., & Almedin, A. (2020) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2020.5.3.0115
Guideline concordance of bisphosphonates used for osteoporosis in a University Hospital, Thailand
Anusathitwattana, S., Sa-ngasoongsong, P., Montakantikul, P., Lekpittaya, N., & Chindavijak, B. (2021) · Pharmaceutical Sciences Asia · doi:10.29090/psa.2021.01.19.089
Fairaq, A., Sulimani2, B., AlAhmadi2, G., Hijii2, N. A., Alessa, R., AlHarthi2, S., & Alhindi1, Y. (2021) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v15i1.13524
Endocrine Complications Following Hematopoietic Cell Transplantation
West, M. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_37
Chen, R., Liu, S.-Y., Huang, M., Ding, N., Wang, Q., Xie, Z., Liu, H., Sheng, Z., & Ou, Y. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-020-00857-7
Nghiên cứu nguy cơ gãy xương theo mô hình FRAX trên đối tượng nữ thừa cân - béo phì trên 45 tuổi
Luu, N. G., Lê, A. T., & Nguyen, H. N. (2021) · Vietnam Journal of Diabetes and Endocrinology · doi:10.47122/vjde.2019.37.5
Prevenzione delle fratture da fragilità e modello di rete polispecialistica
Migliaccio, S., Resmini, G., & Iolascon, G. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00819-2
“1), alla luce del quale i provvedimenti intrapresi per curare una malattia e, in questo caso, per prevenire le frattura da fragilità [13, 14] devono essere adeguati, utilizzando le risorse disponibili che sono limitate e debbono, quindi, essere utilizzate in maniera corretta e appropriata.”
BackgroundRamos, M. A. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/12772
Birinci Basamakta Osteoporoz Risk Ölçeği Kullanımı
ÖKSÜZ, S., & Öngel, K. (2021) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.809235
Special nutritional requirements in the elderly patient undergoing bariatric surgery
Sarmiento, A., Carbajal, R., & Lisson, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822922-4.00008-9
Short-term effects of COVID-19 on risk of traumatic fractures in China: a multi-city studyPreprint
Lv, H., Zhang, X., Wang, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-181106/v1
Surowiec, R. K. (2019) · Deep Blue (University of Michigan)
Lee, J. H., Kim, Y. J., Kim, S. W., Kim, H., Han, W., & Ku, S. (2021) · Science Progress · doi:10.1177/00368504211000515
“Osteoporosis is a ‘‘silent disease’’ with rare symptoms in its early stages, and often goes undiagnosed until severe fractures occur.(13,14) Therefore, the 2 Science Progress”
BackgroundAndrogen Deprivation Therapy for Patients with Intact Prostates Undergoing Radiation Therapy
Dee, E. C., & Nguyen, P. L. (2021) · Practical guides in radiation oncology · doi:10.1007/978-3-030-65137-4_3
Renal Safety of Bisphosphonates– A Systematic Review
Prajith, V. (2021) · INTERNATIONAL JOURNAL OF MEDICAL AND CLINICAL CASE REPORTS · doi:10.51521/ijmccr.2021.1105
Freitas, A., da Silva, L. D. L., Costa, R. R., et al. (2021) · Revista Brasileira de Ortopedia · doi:10.1055/s-0040-1721832
WITHDRAWN: Understanding Osteoporosis Screening Practices in Men: A Nationwide Physician Survey
Choksi, P. U., Gay, B. L., Reyes‐Gastelum, D., Haymart, M. R., & Papaleontiou, M. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.05.002
RetractedDoerr-Kashani, P. (2015) · USF Scholarship Repository (University of San Francisco)
Seminarios de la Fundación Española de Reumatología
de Jesus, M. C. P., Arias, G., Alberto, J., & García-Vadillo, A. (2016)
Terlemez, R., İnceoğlu, S. Ç., Günerli, M., Doğu, B., Yılmaz, F., & Kuran, B. (2021) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2020.71463
Valero, C., Olmos, J. M., Llorca, J., et al. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01228-z
Viun, T. I., Viun, S. V., Andrusha, A. B., & Marchenko, A. (2021) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2021.01.121
Controversias sobre el rastreo de los niveles séricos de vitamina D y su suplementación
Yoo, C. Y., ́Abate, V. E. A. D., & Botargues, M. (2018) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v20i4.6739
Freitas, A., Silva, L. D. L. D., Costa, R. R., et al. (2021) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Chronic obstructive disease and comorbidities (literature review)
Stavila, E., Botnaru, V., Rusu, D., & Corlăteanu, A. (2021) · Bulletin of the Academy of Sciences of Moldova Medical Sciences · doi:10.52692/1857-0011.2021.1-69.33 · Cited by 2
Focus on the management of osteoporosis
Maroc., L. D. C. T. F. D. M. E. D. P. R. –., Ifezouane, J., Berdi, F., Tadlaoui, Y., Marrakchi, S. E., Maroc., L. D. D. M. E. D. L. P. R. –., & Lamsaouri, J. (2021) · Batna Journal of Medical Sciences (BJMS) · doi:10.48087/bjmsra.2021.8112 · Cited by 1
Zhang, H., Lin, Z., Jiping, Z., et al. (2020) · doi:10.21203/rs.3.rs-35365/v1
“Light exposure is also bene cial to reduce the incidence of hip fractures, via increasing the source of vitamin D, promoting calcium absorption which are all crucial for bone health and muscle performance [11, 12].”
Backgroundde Andrade, E. L., da Silva, D. P., & de Pontes, J. L. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504102
Comparison of 2 fracture risk estimation processes in Alberta: a cross-sectional chart review
Riar, S. S., Feasel, A. L., Aghajafari, F., Frohlich, D., Symonds, C. J., Kline, G. A., & Billington, E. O. (2021) · CMAJ Open · doi:10.9778/cmajo.20200207
INTERVENÇÃO FISIOTERAPÊUTICA NO TRANSTORNO DO ESPECTRO AUTISTA INFANTIL: RELATO DE CASO
Donadeli, B. A. V., Naldi, F. C. R. T., Borges, A. P. O., & Alves, E. M. M. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504131
Costa, D. P., de França, T. L. B., Hull, E. L., Pereira, S. A., & Sousa, K. G. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504139
A PRÁTICA DA GINÁSTICA LABORAL COMO MEDIDA PREVENTIVA DE DOENÇAS OCUPACIONAIS
Pinheiro, C. D. P. D. S., Lima, A. L. R., Pinheiro, A. P. D. S., de Quadros, F. G. S., Oliveira, P. D. S., Silva, A. M. F. D., Fernandes, B. T. D. S., Oliveira, F. D. S., dos Santos, D. S., & Sandim, D. P. R. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504101 · Cited by 1
FOTOBIOMODULAÇÃO E TREINAMENTO SENSÓRIO-MOTOR APLICADOS A MULHERES COM OSTEOARTRITE DE JOELHO
Balão, A. B., Vassão, P. G., & Rennó, A. C. M. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504038
Role of Vitamin D3 in fracture union in adults
Arora, A., & Singh, A. K. (2021) · IP International Journal of Orthopaedic Rheumatology · doi:10.18231/j.ijor.2021.009
ANÁLISE DA MOTRICIDADE EM CRIANÇAS COM SÍNDROME DE DOWN, POR MEIO DA ESCALA DE DESENVOLVIMENTO MOTOR
de Andrade, E. L., da Silva, D. P., dos Santo, C. P., & da Costa, C. K. L. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504064
EFEITOS DA INTERVENÇÃO PRECOCE NO DESENVOLVIMENTO INFANTIL DO RECÉM-NASCIDO
Ferreira, D. S., Silva, R. A. B., de Carvalho, D. B., & Sousa, B. L. S. C. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504142
Análise do consumo máximo de oxigênio a partir do teste ergométrico em cardiopatas
Alves, L. D. O., Gomiero, L. A. A., dos Santos, M. E. A. M., & Bachur, C. K. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504066
Araújo, M. C. M., Carvalho, F. N., Rodrigues, N. D. O., Gonzaga, I. C. A., & Araújo, G. A. F. B. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504059
Silva, Í. J. F. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504050
de Miranda, T. S., Almeida, G. D. S., Alves, E. M. F., & Fonsêca, R. C. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504025
Nascimento, A. F., Freire, B. D. R., & da Silva, A. Q. G. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/210504056
Effectiveness of Exercise on Osteosarcopenia in Elderly People: A Protocol Systematic ReviewPreprint
Souza, G. V. E., Noll, M. A., & Silveira, É. A. (2020) · Research Square · doi:10.21203/rs.3.rs-45898/v1
“Abbreviations BMD – Bone mineral density; DEXA – Absorption of double energy by X-rays; PE – Physical exercise; PRISMA-P – Preferred Reporting Items for Systematic review and Meta-Analysis Protocols; WHO – World Page 6/8 Health Organization; EWGSOP – European Working Group on Sarcopenic in Older People; GRADE – Gradin…”
BackgroundExcellent outcome of a patient with acute back pain and osteoporotic fracture- A case report
Nallasivan, S., Vignesh, R. S., & Govindarajan, A. (2021) · IP International Journal of Orthopaedic Rheumatology · doi:10.18231/j.ijor.2021.012
Sukhorukikh, M., Козлова, М. В., Gorbatova, E., et al. (2021) · Archiv Euromedica · doi:10.35630/2199-885x/2021/11/2/29
“The first-line drugs in the treatment of postmenopausal OP are bisphosphonates (BP), whose pharmacokinetics vary, which is associated with the characteristics of the chemical structure and reflects the degree of therapeutic doses [8, 11].”
BackgroundA mozgásterápia szerepe az osteoporosis megelőzésében és kezelésében
Pósa, G., Róka, E., & Koncsek, K. (2016) · Magyar Traumatológia Ortopédia Kézsebészet Plasztikai Sebészet · doi:10.21755/mto.2016.059.0304.005
Osteoporoz ile Takipli Hastalarda GelişenKalça Kırığ ı Sıklığ ının Değ erlendirilmesi
Özgen, M., Atik, Z., Armağan, O., et al. (2020) · DergiPark (Istanbul University)
Age-related changes in bone tissue in men
Musiіenko, А. S., & Zaverukha, N. V. (2021) · PAIN JOINTS SPINE · doi:10.22141/2224-1507.11.2.2021.236564
“The Z-score of > -2 SD corresponds with the BMD within the reference values for a certain age, the Z-score of < -2 SD corresponds with the low BMD (under the reference values for a certain age) [10, 11].”
BackgroundPostmenopozal Osteoporozda Paraoksonaz 1L55M ve Q192R Polimorfizminin İ lişkisininDeğ erlendirilmesi
Özgen, M., Coşan, D. T., Atik, Z., Saydam, F., Çolak, E., Soyocak, A., Doğaner, F., Berkan, F., Değirmenci, İ., & Mutlu, F. (2020) · DergiPark (Istanbul University)
Organization of primary medical care for patients with osteoporosis
Gladkova, E. N. (2021) · Russian Family Doctor · doi:10.17816/rfd71151
Behandlungsstrategien der Osteoporose
Bartl, R., & Bärtl, C. (2021) · Springer eBooks · doi:10.1007/978-3-662-62528-6_16
Ostéoporose masculine : des recommandations pour améliorer sa prise en charge
Debiais, F. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.05.009 · Cited by 1
Managing Cost and Quality in Musculoskeletal Care
Egan, C. R., Roy, A. E., & Iorio, R. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-74625-4_34
Osteoporosis Screening as a Model for Effective Preventive Healthcare in Concierge MedicinePreprint
Wheeless, C. J., Yates, S. W., & Schrader, M. K. (2019) · Research Square · doi:10.21203/rs.2.13813/v1
“An history of rheumatoid arthritis or medications associated with lowering bone mass call for BMD testing [19].”
BackgroundCOVID-19: Tendências em mudança e seu impacto no futuro da odontologia.
Olmos, J. M., Arnaiz, F., Hernández, J. L., Olmos-Martínez, J. M., & Macías, J. G. (2021) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2021v3n6p72-84
Bandyopadhyay, K., Ray, S., Shikha, D., Bhalla, G. S., & Khetan, A. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.04.008 · Cited by 1
How to Identify Individuals Requiring Anti-osteoporosis Therapy: Imaging in Bone Health
Fuggle, N. R., & Ward, K. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-78128-6_2
Is silence golden… In this context, not so much
Lyles, K. W., Riska, K. M., & Smith, S. L. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17444
“Since the description by Dr Fuller Albright of postmenopausal osteoporosis in 1945, almost every description of the disorder has stated that osteoporosis is silent until a fracture occurs.(2,3) The paper “Osteoporosis, Bisphosphonate Use, and Risk ofModerate orWorse Hearing Loss inWomen” recently published by Curhan e…”
BackgroundThe Role of Osteoporosis and Bone Diseases in Revision Spine Surgery
Anderson, P. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71201-9.00002-0
Mahajan, S. M., Raina, R., & Jhobta, A. (2021) · Eastern Journal of Medical Sciences · doi:10.32677/ejms.v6i2.2930
Critical Issues in Osteoporosis Management
Wong‐Pack, M., Cummings, K., Lau, A. N., & Adachi, J. D. (2021) · Wiley eBooks · doi:10.1002/9781119413936.ch7
Alvos terapêuticos em osteoporose
Domiciano, D. S. (2019) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2019.18.2.15-20
FEATURES OF MANAGEMENT IN PATIENTS WITH OSTEOPOROSIS AND DIABETES MELLITUS
Zhuravlyova, L., Oliinyk, M., & Sikalo, Y. K. (2021) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2021.3.16
Işıkçı, N. İ., Abuqbeitah, M., & Demır, M. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.08.003
Nisa, K. U., Rehman, A. U., & Hani, U. (2021) · Research Square · doi:10.21203/rs.3.rs-805024/v1
Risk Assessment of Jawbone Fracture by Mandibular Cortical Bone Width Using Computed Tomography
Itakura, G., Ito, K., Muraoka, H., et al. (2021) · Journal of Hard Tissue Biology · doi:10.2485/jhtb.30.379
Yu, S., Chen, J., Chen, Y., Wang, Y., Hsu, C., Lai, H., He, H.-R., & Cheng, T. (2021) · Research Square · doi:10.21203/rs.3.rs-944340/v1
Drug Candidates for Covid-19 Treatment in Brazil
Silva, L. P. (2021) · Clinical Cardiology and Cardiovascular Interventions · doi:10.31579/2641-0419/200
Additional tools for the estimation of fracture risk using DXA method
Vako, L. R. (2021) · Journal of Research and Practice on the Musculoskeletal System · doi:10.22540/jrpms-05-140
Cellular and Molecular Biology in Bone Remodeling
DeNapoli, R. C., Buettmann, E. G., & Donahue, H. J. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_1 · Cited by 1
Application of SOR to nonlinear reactor problems
Cheng, H., LU, L., Aronson, A. L., et al. (1978) · Transactions of the American Nuclear Society
McNamara, E. A., Malabanan, A. O., Abate, E. G., et al. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.03.006
The Short Term Impact of a Mediterranean-Style Diet on Bone Markers in Post-Menopausal Women
Garrett, A. E. (2014) · OpenCommons - UConn (University of Connecticut)
J.D.サリンジャー論 : 『ナイン・ストーリーズ』をめぐって
高橋, 美. (1995) · 桐原書店 eBooks
Las hormigas de Macondo. Trayectorias y desafíos de los “sin comunicación” en América Latina
Gomes, G. M. (2011) · Redes.com : revista de estudios para el desarrollo social de la Comunicación
Seychelles: las islas del tesoro
Velasco, M. (2000) · Historia y vida
Kemik Mineral Dansitesi ile Biyokimyasal Parametreler Arasındaki İlişki
Durmaz, A., & Özdemir, Ç. (2021) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.973194
Napoli, N. (2021) · Journal of Gerontology and Geriatrics · doi:10.36150/2499-6564-n456
Current pharmacotherapy of osteoporosis and its future
Kukowka, A., Pluskota, M., Arciszewski, M., & Sroczyński, T. (2021) · Farmacja Polska · doi:10.32383/farmpol/145401 · Cited by 2
Association of Primary Sarcopenia with Serum MMP2, TIMP2 Levels, and MMP2/TIMP2 Ratio
Suzan, V., Kanat, B. B., Yavuzer, H., Bolayırlı, M., Döventaş, A., & Erdinçler, D. S. (2022) · European Journal of Geriatrics and Gerontology · doi:10.4274/ejgg.galenos.2021.2021-10-3
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_12
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.